Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMA Recommends Sanofi Pasteur A(H1N1) Vaccine Humenza
The CHMP has recommended the marketing authorisation of Humenza vaccine in EU countries for the active immunisation of persons 6 months of age and older against influenza disease
The CHMP has recommended the marketing authorisation of Humenza vaccine in EU countries for the active immunisation of persons 6 months of age and older against influenza disease
Lapatinib, in combination with an aromatase inhibitor (AI), is indicated for the treatment of post-menopausal women with hormone receptor (HR)-positive, HER2 (ErbB2) over-expressing metastatic breast cancer. The patients
Cilag International has given Basilea Pharmaceutica a notice of termination of the worldwide license, development and co-promotion agreement between the parties. The compound, including pending applications and in-market
MIT currently produces the 1000 Rapid Microbial Identification (ID) System that can identify bacteria in less than five minutes with a laser that uses the principles of light
The instrument removes a key bottleneck in the current workflow for sequencing by replacing the tedious gel isolation and purification steps used for size selection of sheared genomic
Hematide, a synthetic, peptide-based erythropoiesis-stimulating agent (ESA), is designed to act on the erythropoietin receptors and stimulate the production of red blood cells by dosing once every four
In the study, 1,000 healthy volunteers aged 18 to 64 years old were enrolled to receive two doses of 5mcg, 15mcg or 45mcg of Novavax’s 2009 H1N1 influenza
Athens, Ohio-based Diagnostic Hybrids, is a manufacturer of direct fluorescent in vitro diagnostic assays used in hospital and reference laboratories for a variety of diseases, including viral respiratory
PPD is expecting that the offices will strengthen its full range of drug discovery and development services and continue to position it to capitalise on the growth of
Horizant is an investigational treatment for moderate-to-severe primary Restless Legs Syndrome developed by Xenoport and licensed to GlaxoSmithKline. Depomed noted that unlike Horizant, its proprietary extended release formulations